Recent Security Class Actions

Ultragenyx Pharmaceutical Inc. Common Stock (NASDAQ: RARE)

Company Name:Ultragenyx Pharmaceutical Inc. Common Stock
Stock Symbol:NASDAQ: RARE
Class Period Start:08/03/2023
Class Period End (inclusive):12/26/2025
Filing Deadline:04/06/2026

The Complaint alleges that, during the class period, defendants provided investors with material information concerning Ultragenyx's expected results for its Phase III Orbit and Cosmic Studies, which tested setrusumab (UX 143) in patients with Osteogenesis Imperfecta ("OI"). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately trigger a decrease in the OI patients' annualized fracture rate, alongside confidence in the study designs to demonstrate such ability and reduce testing variability that could interfere with such a result.